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The etiology of colon cancer is a complex phenomenon that involves both genetic 
and environmental factors.  However, only about 20% have a familial basis with the 
largest fraction being attributed to environmental causes that can lead to chronic 
inflammation.  Tumors associated macrophages drive the pro-inflammatory response in 
the tumor micro-environment and are associated with poor prognosis in certain cancers.  
Monocyte chemoattractant protein 1 (MCP-1) is thought to be the most important 
chemokine for recruitment of macrophages to the tumor microenvironment.   In chapter 
1, we examined the timing and magnitude of the intestinal inflammatory cytokine 
response in relation to tumorigenesis in the Apc
Min/+
 mouse.  Then, in chapter 2, we 
examined the role of MCP-1 on tumor associated macrophages, inflammation, and 
intestinal tumorigenesis in Apc
Min/+
 mice.  In chapter 3, we examined the effects of 
exercise on markers associated with macrophages and select T cell populations in 
Apc
Min/+
 mice and related this to polyp characteristics.  The results in chapter 1 show that 
the increase in polyp burden with age is positively correlated with the increase in 
intestinal inflammatory cytokine expression (mRNA and protein) of MCP-1, IL-1β, IL-6 
and TNF-α, with MCP-1 showing the highest association. Similarly, circulating MCP-1 
was increased at 12 wks (P<0.05) and then again at 20 wks (P<0.05).  MCP-1 deficiency 
decreased overall polyp number by 20% and specifically large polyp number by 45% 
(P<0.05).  In chapter 2, we show that MCP-1 deficiency decreased F4/80 positive cells in 
both the polyp tissue and surrounding intestinal tissue (P<0.05) as well as expression of 
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markers associated with M1 (IL-12 & IL-23) and M2 macrophages (IL-13, CD206, TGFβ 
& CCL17) (P<0.05).  MCP-1 knockout was also associated with increased CTLs and 
decreased Tregs (P<0.05).  In chapter 3, we show that while there was no significant 
difference in overall polyp number between the groups (Sed: 23.3 ± 4.3 and Ex: 16.5 ± 
4.3), Ex did have a reduction in the number of large polyps (Sed:6.1 ± 1.1 and Ex: 3.0 ± 
0.6) (P<0.05).  Similarly, Ex reduced mRNA expression of overall macrophages (F4/80) 
as well as markers associated with both M1 (IL-12) and M2 (CD206, CCL22, & Arg-1) 
subtypes (P<0.05).  CD8 expression was increased while Foxp3 expression was 
decreased with Ex (P<0.05).  We demonstrate that MCP-1 is an important mediator of 
tumor growth and immune regulation that may serve as an important biomarker and/or 
therapeutic target in colon cancer.  This data also provides important new information on 
immune regulation as a possible mechanism for the documented benefits of exercise 
training on reducing colon cancer progression.  
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 Colon cancer is the third most commonly diagnosed cancer among men and 
women in the United States (cancer.org).  It is estimated that over 98,000 new cases will 
be diagnosed in 2014, causing over 50,000 deaths.  The risk of developing colon cancer is 
5% for men and women combined, and many of the risk factors are environmental and 
thus preventable.  These preventable risk factors include physical inactivity, obesity, 
smoking, and heavy alcohol use (cancer.org).  These environmental factors cause chronic 
inflammation driving the promotion, invasion, and metastasis of colon cancer.  
Inflammation involves the interaction between multiple factors to promote colon cancer 
progression.  Cytokines, chemokines, and immune cells will be discussed, as well as a 
possible mechanism for the beneficial effects of physical activity on colon cancer 
progression. 
The link between inflammation and cancer has been well established.  
Inflammation has been linked to every step involved in the development and progression 
of colon cancer, including cellular transformation, promotion, survival, proliferation, 
invasion, angiogenesis, and metastasis (1-5).  Hanahan and Weinberg have named 
inflammation as the 7
th
 hallmark of cancer (6).  The inflammatory cytokines interleukin 
1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α), largely produced 
by macrophages, have all been associated with poor outcome in colon cancer (1-4).  In 
fact, we have previously shown that IL-6 overexpression using electron gene transfer 
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techniques can increase polyp burden in the Apc
Min/+
 mouse model of intestinal 
tumorigenesis (7).  Similarly monocyte chemoattractant protein 1 (MCP-1), a major 
chemokine for macrophage recruitment, has been associated with increased grade of the 
tumor in certain cancers (8, 9).  While the link between inflammatory cytokines and 
colon cancer is well recognized, the timing and magnitude of this response in relation to 
tumorigenesis has not been described. 
Previously it was thought that infiltration of immune cells into the tumor 
microenvironment would have antitumor effects but in recent years, it has been shown 
that these tumor-associated immune cells actually enhance the neoplastic capabilities of 
cells within the tumor microenvironment (6, 10-13).  Multiple immune cell types are 
found within tumors which may be tumor-inhibiting or tumor-promoting.  For example, 
cytotoxic T lymphocytes (CTLs) are tumor-inhibiting and patients with a higher 
percentage of these cells in the tumor have a better prognosis (6).  On the other hand, 
patients with a higher percentage of macrophages in general have a worse prognosis (14-
18).  Therefore, identifying strategies to alter the responses of tumor-associated immune 
cells may have important implications for the progression of colon cancer. 
MCP-1, also known as chemokine (C-C motif) ligand 2 (CCL2), has been 
identified as an essential chemokine for monocyte trafficking (19-21).  Using targeted 
gene disruption Lu et. al (1998) created an MCP-1 deficient mouse and documented that 
MCP-1 is uniquely essential for monocyte recruitment in several inflammatory models 
(20).  More recently in cancer models, MCP-1 has been suggested to be the most 
important chemokine for macrophage recruitment to the tumor microenvironment (22); 
both rodent and clinical studies have associated MCP-1 levels with tumor-associated 
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macrophage (TAM) abundance and subsequent cancer progression (23-25).  For example, 
we have shown that MCP-1 is correlated with abundance of large polyps in the Apc
Min/+
 
mouse model of intestinal tumorigenesis.  Similarly, Bailey et al. has reported that MCP-
1 expression is associated with TAM number and stage of colorectal cancer in humans 
(24).  Further, in a model of colitis-associated colon cancer it has been reported that mice 
deficient for an MCP-1 specific receptor have less macrophage infiltration, reduced 
COX-2 expression, and decreased tumor size (25).  However, the specific role of MCP-1 
on macrophage number and phenotype, inflammatory processes, and tumor progression 
in a genetic mouse model of colon cancer has yet to be determined.  
Physical inactivity has been reported to account for 10% of all colon cancer cases 
(26), whereas physical activity has been associated with reduced risk for incidence of 
colon cancer.  This inverse relationship between physical activity and colon cancer risk is 
supported by epidemiological studies as well as controlled experimental studies using 
rodent models.  For example, nine weeks of treadmill running has been reported to 
decrease the total number of intestinal polyps as well as the number of large polyps in the 
Apc
Min/+
 mouse model of intestinal tumorigenesis (27).  Similarly a recent study in a 
multiethnic colon cancer screening population reported that exercising for one hour per 
week was associated with a lower prevalence of polyps and adenomas when compared to 
those who exercised less or not at all (28).  
The mechanisms responsible for a preventative effect of exercise on colon cancer 
risk are complex and multifaceted.  An exercise-induced alteration in immune system 
function is one possible mechanism that has not been widely explored.  Exercise has been 
reported to influence macrophage behavior in various disease models.  For instance, it 
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has been shown that exercise can reduce macrophage-mediated inflammation in an obese 
mouse model (29).  Similarly, macrophage infiltration associated with the reversal of 
arterial inflammation was decreased by exercise training in aged mice (30). However, 
while it is well established that macrophages play a significant role in the pathogenesis of 
colon cancer and that exercise can influence the macrophage response, there is very little 
evidence on the benefits of exercise on macrophage behavior in the presence of colon 
cancer. 
T cells have been shown to be altered by exercise (31, 32).  It is well recognized 
that cytotoxic T lymphocytes (CTLs) constitute one of the most important effector 
mechanisms of anti-tumor immunity (33, 34).  For example, adoptive transfer of CD8+ 
cells controls the growth of B16 melanoma in mice (35).  On the other hand, regulatory T 
cells (Tregs) have been associated with accelerated tumor growth and immune evasion 
through their inhibitory actions on CTLs and helper T cells (36, 37).  The T cell response 
to exercise has been reported to be highly variable and is likely dependent on the mode, 
intensity and duration of exercise.  However, to date there is no evidence on the effects of 
exercise on T cells in a mouse model of colon cancer.  
The Apc
Min/+ 
mouse model has been the most widely used genetically engineered 
mouse model for cancer studies that involve the gastro-intestinal tract (38, 39).  It was the 
first mouse model to be generated by mutation of the ademonatous polyposis coli (Apc) 
gene through random chemical carcinogenesis (40).  This gene is similarly mutated in 
patients with familial adenomatous polyposis (41).  It has been shown to be responsive to 
treatment with anti-inflammatory agents, including both anti-inflammatory dietary 
supplements as well as non-steroidal anti-inflammatory drugs (NSAIDs) (38, 39).   
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The purpose of the first study was to examine the temporal sequence and 
magnitude of the inflammatory cytokine response in relation to tumorigenesis in the 
Apc
Min/+
 mouse to lead to the development of inflammatory mediator biomarkers to 
assess progression of this disease, and further, allow for the determination of appropriate 
timing of effective treatments to target inflammatory processes in this mouse model.  The 
results from this study showed that gene expression of MCP-1 was highly correlated with 
large polyp number.  In the second study, our aim was to examine the role of MCP-1 in 
colorectal cancer in the Apc
Min/+
 mouse.  The MCP-1 knockout mouse was crossed with 
the Apc
Min/+
 mouse to generate a mouse model of intestinal tumorigenesis deficient for 
MCP-1.  With this mouse model we were able to determine the role of MCP-1 on 
macrophage recruitment and phenotype in the tumor microenvironment.  We show that 
MCP-1 deficiency in our model of intestinal tumorigenesis leads to a decrease in the total 
number of polyps as well as the number of large polyps, confirming the association 
between MCP-1 and large polyp number seen previously.  The purpose of the third study 
was to determine if the effects of exercise on the immune response could be a mechanism 
for the beneficial effects of exercise on tumorigenesis in this model.  We show that 
overall, certain markers associated with both the M1 and the M2 macrophage phenotype 
were reduced in Apc
Min/+
 mice following exercise.  Additionally, exercise resulted in an 
increased expression of CD8 and decreased expression of Foxp3, markers for CTLs and 
Tregs, respectively.  These alterations in immune cell parameters following exercise 
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The etiology of colon cancer is a complex phenomenon that involves both genetic 
and environmental factors.  However, only about 20% have a familial basis with the 
largest fraction being attributed to environmental causes that can lead to chronic 
inflammation.  While the link between inflammation and colon cancer is well established, 
the temporal sequence of the inflammatory response in relation to tumorigenesis has not 
been characterized.  We examined the timing and magnitude of the intestinal 
inflammatory cytokine response in relation to tumorigenesis in the Apc
Min/+
 mouse.  
Apc
Min/+
 mice and wildtype mice were sacrificed at one of 4 time-points: 8, 12, 16, and 20 
wks of age.  Intestinal tissue was analyzed for polyp burden (sections 1, 4 and 5) and 
mRNA expression and protein concentration of MCP-1, IL-1β, IL-6 and TNF-α (sections 
2 and 3).  The results show that polyp burden was increased at 12, 16 and 20 wks 
compared to 8 wks (P<0.05).  Gene expression (mRNA) of MCP-1, IL-1β, IL-6 and 
TNF-α was increased in sections 2 and 3 starting at wk 12 (P<0.05), with further 
increases in MCP-1, IL-1β and IL-6 at 16 wks (P<0.05).  Protein concentration for these 
cytokines followed a similar pattern in section 3.  Similarly, circulating MCP-1 was 
increased at 12 wks (P<0.05) and then again at 20 wks (P<0.05).  In general, overall 
polyp number and abundance of large polyps were significantly correlated with the 
inflammatory cytokine response providing further support for a relationship between 
polyp progression and these markers.  These data confirm the association between 
intestinal cytokines and tumorigenesis in the Apc
Min/+
 mouse and provide new 
information on the timing and magnitude of this response in relation to polyp 
development.  These findings may lead to the development of inflammatory mediators as 
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important biomarkers for colon cancer progression.  Further, these data may be relevant 
in the design of future investigations of therapeutic interventions to effectively target 
inflammatory processes in rodent models.   
INTRODUCTION 
Colon cancer is a significant global health concern; despite advances in detection, 
surgery and chemopreventive treatment it remains the third most common malignancy 
and the fourth most common cause of cancer mortality worldwide (42-44).   The etiology 
of colon cancer is a complex phenomenon that involves contribution from both genetic 
and environmental factors.  However, only about 20% of colon cancer cases can be 
attributed to genetic factors (45) with the vast majority of cases being ascribed to 
environmental causes that can lead to chronic inflammation.  For example, inflammatory 
bowel disease (IBD), ulcerative colitis (UC) and Crohn’s colitis, all of which display 
chronic inflammation of the gastrointestinal mucosa, are associated with increased risk 
for the development of colon cancer (46, 47).   
 The link between inflammation and colon cancer is well established; 
inflammation has been linked to every step involved in the development and progression 
of colon cancer, including cellular transformation, promotion, survival, proliferation, 
invasion, angiogenesis, and metastasis (1-5).  Furthermore, chronic inflammation has 
been associated with “sickness behaviors” including circadian disruptions, anorexia, 
cachexia, fatigue, and decreased physical activity all of which can lead to a decreased 
quality of life, as well as poorer prognosis and survival in cancer patients (48-50).  The 
inflammatory cytokines interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis 
factor-α (TNF-α), largely produced by macrophages, have all been associated with poor 
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outcome in colon cancer (1-4).  In fact, we have previously shown that IL-6 
overexpression using electron gene transfer techniques can increase polyp burden in the 
Apc
Min/+
 mouse model of intestinal tumorigenesis (7).   Similarly monocyte 
chemoattractant protein 1 (MCP-1), a major chemokine for macrophage recruitment, has 
been associated with increased grade of the tumor in certain cancers (8, 9).    While the 
link between inflammatory cytokines and colon cancer is well recognized, the timing and 
magnitude of this response in relation to tumorigenesis has not been described. 
The Apc
Min/+ 
mouse model has been the most widely used genetically engineered 
mouse model for cancer studies that involve the gastro-intestinal tract (38, 39).  It was the 
first mouse model to be generated by mutation of the ademonatous polyposis coli (Apc) 
gene through random chemical carcinogenesis (40).  This gene is similarly mutated in 
patients with familial adenomatous polyposis (41).  It has been shown to be responsive to 
treatment with anti-inflammatory agents, including both anti-inflammatory dietary 
supplements as well as non-steroidal anti-inflammatory drugs (NSAIDs) (38, 39).  
Despite this, intestinal inflammation has not been characterized in this model; to our 
knowledge there are no studies that have examined the relationship between 
inflammatory cytokines and tumor burden in the Apc
Min/+ 
mouse.  The purpose of this 
study was to examine the temporal sequence and magnitude of the inflammatory cytokine 
response in relation to tumorigenesis in the Apc
Min/+
 mouse. This may lead to the 
development of inflammatory mediators as important biomarkers to assess progression of 
this disease, and further, allow for the determination of appropriate timing of effective 




MATERIALS AND METHODS 
2.1 Animals.  Apc
Min/+
 male mice on a C57BL/6 background (Jackson Laboratories)
 
were 
purchased and bred with female C57BL/6 mice in the University
 
of South Carolina’s 
Center for Colon Cancer Research (CCCR). Offspring were
 
genotyped as heterozygotes 
by RT-PCR for the Apc gene by taking
 




TTCCACTTTGGCATAAGGC-3’.  Female Apc
Min/+
 offspring were randomly assigned 
to one of four different timepoints: 8, 12, 16 or 20 wks of age (n=8-12/group).  Wildtype 
C57BL/6 mice were used as age matched controls (n=6-11/group).  Mice were 
maintained on a 12:12 h light-dark cycle in a low-stress environment (22
o
C, 50% 
humidity and low noise) and provided food and water ad libitum. All animal 
experimentation
 
was approved by the University of South Carolina’s Institutional
 
Animal 
Care and Use Committee. 
2.2 Tissue collection.  Mice were sacrificed at their respective group age (8, 12, 16 or 20 
wks) for tissue collection using isoflurane overdose. All mice were sacrificed in the 
mornings between 9:00 and 11:00am.  The small intestine was carefully
 
dissected distally 
to the stomach and proximal to the cecum.
  
The large intestine (section 5) was removed 
from the distal end of the cecum
 
to the anus.  Mesentery tissue was removed with 
tweezers, and
 
the small intestine was cut into four equal sections (sections 1-4). All 
intestinal
 
sections were flushed with PBS, opened longitudinally, and flattened
 
with a 
cotton swab. Sections 1 and 4 of the small intestine and the large intestine (section 5) 
were fixed in 10% buffered
 
formalin (Fisher Scientific, Pittsburg, PA) for 24 h. Sections 
2 and 3 were divided into 2 equal parts and mucosal scrapings were performed in iscoves 
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medium (Invitrogen, Carlsbad, CA) (containing 5% fetal bovine serum and a cocktail 
enzyme inhibitor (10 mM EDTA, 5 mM benzamidine HCl, and 0.2 mM phenylmethyl 
sulfonyl fluoride)) and TRIzol reagent (Invitrogen, Carlsbad, CA) for protein and gene 
expression analysis, respectively. Samples were stored at –80°C until analysis of 
inflammatory mediators. Blood was collected from the inferior vena cava using a 
heparinized syringe and spun in a microcentrifuge at 4,000rpm for 15 min.  Plasma was 
then stored at –80
o
C until assayed for MCP-1.  
2.3 Polyp counts. Formalin-fixed intestinal sections from all animals were rinsed
 
in 
deionized water, briefly stained in 0.1% methylene blue,
 
and counted by the same 
investigator who was blinded to the
 
treatments. Polyps were counted under a dissecting 
microscope,
 
using tweezers to pick through the intestinal villi and identify
 
polyps. Polyps 
were categorized by size (>2 mm, 1–2 mm, and <1 mm).   
2.4 Expression of inflammatory markers.  Procedures for RNA isolation from mucosal 
scrapings were performed as previously described (51, 52).  Briefly, mucosal tissue was 
homogenized under liquid nitrogen with a polytron,
 
and total RNA was extracted using 
TRIzol reagent (Invitrogen, Carlsbad, CA). The extracted RNA (2.5 µL of
 
sample) was 
dissolved in DEPC-treated water
 
and quantified spectrophotometrically at 260-nm 
wavelength.  RNA quality was assessed on an Agylent 2100 BioAnalyzer.  RNA was 
reverse transcribed into cDNA in a 50 µL reaction volume containing 19.25 µL RNA (1.5 
µg) in Rnase-free water, 5 µL 10X RT Buffer, 11 µL 25 mM MgCl2, 10 µL deoxyNTPs 
mixture, 2.5 µL random hexamers, 1 µL Rnase inhibitor, and 1.25 µL multiscribe reverse 
transcriptase (50U/µL). Reverse transcription was performed at 25
o
C for 10 min, 37
o
C 
for 60 min, and 95
o





until subsequent amplification. Quantitative Real-Time Polymerase Chain Reaction (RT-
PCR) analysis was done per manufacturer’s instructions (Applied Biosystems, Foster 
City, CA) using TaqMan Gene Expression Assays (IL-1β, IL-6, TNF-α and MCP-1).  
DNA amplification was carried out in 12.5 µL Taqman Universal PCR Master Mix 
(AmpliTaq Gold DNA Polymerase, Passive Reference 1, Buffer, dNTPs, AmpErase 
UNG), 1 µL cDNA, 9 µL Rnase-free water, and 1.25 µL 18S primer (VIC) and 1.25 µL 
primer (FAM) (for endogenous reference and target gene) in a final volume of 25 
µL/well. Samples were loaded in a MicroAmp 96-well reaction plate. Plates were run 
using Applied Biosystems Sequence Detection System. After 2 min at 50
o
C and 10 min 
at 95
o
C, samples were coamplified by 50 repeated cycles of which one cycle consisted of 
15 s denaturing step at 95
o
C and 1 min annealing/extending step at 60
o
C. Data were 
analyzed using Applied Biosystems software using the CT, cycle threshold, which is the 
value calculated and based on the time (measured by PCR cycle number) at which the 
reporter fluorescent emission increases beyond a threshold level (based on the 
background fluorescence of the system), and it reflects the cycle number at which the 
cDNA amplification is first detected.  All samples were run in duplicate. 
Quantification of cytokine gene expression for IL-1β, IL-6, TNF-α and MCP-1 were 
calculated using the delta CT method as described by Livak and Schmittgen (2001) (53).  
Briefly, delta CT (CT(FAM) – CT(VIC)) is calculated for each sample and control. Delta 
delta CT (delta CT(control) – delta CT(sample)) is then calculated for each sample and 
relative quantification is calculated as 2 delta delta CT. Initial exclusion criteria consist of 
FAM CT ≥40 and VIC CT ≥23.   Multiple plates were used for each marker, however an 
equal number of samples from each time-point were run on the same plate and all plates 
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were run under the same conditions.   The intra assay variability for all gene expression 
assays was < 1%.  
2.5 Concentration of inflammatory markers.  Mucosal tissue was homogenized using a 
polytron and samples were centrifuged at 10,000 rpm at 4
o
C for 10min, and the 
supernatants removed and stored at 4
o
C prior to the assay of IL-1β, IL-6, TNF- and 
MCP-1 via ELISA (R&D Systems, Minneapolis, MN). The assay was performed 
according to the manufacturer’s instructions. Total soluble protein was also determined 
using supernatant of homogenized samples via bicinchoninic acid (BCA) protein assay 
(Pierce, Rockford, IL.).  Cytokine levels are expressed as a ρg per 100 g total protein.  
Plasma levels of MCP-1 were also measured using ELISA techniques (R&D Systems, 
Minneapolis MN).  As described above, multiple plates were used for each inflammatory 
marker with an equal number of samples from each time-point on the same plate. Intra 
assay and inter assay variability were < 3% and <5%, respectively for all proteins via 
ELISA. 
2.6 Statistical Analysis.  Polyp data was analyzed using a one-way ANOVA (Time) with 
Student Newman-Keuls post-hoc analysis. All inflammatory mediator data were analyzed 
using a two-way ANOVA (Time X Strain) with Student Newman-Keuls post-hoc 
analysis where appropriate.  The correlation coefficients between polyp number and 
inflammatory mediator levels were determined by Spearman correlation analyses. 
Analysis was done using commercial software (SigmaStat, SPSS, Chicago, IL). 






3.1 Polyp incidence.  Polyps were counted on formalin-fixed, methylene blue-stained
 
intestinal sections.  Overall polyp number was increased at 12 (60.3 ±6.3), 16 (63.4 ±7.6) 
and 20 wks (47 ± 4.4) versus 8 wks (26.4 ± 3.2) (P<0.05) (Figure 1.1A) and colon polyps 
at 20 wks (1.4 ± 0.4) were greater than 8 wks (0.28 ± 0.18), but this did not reach 
statistical significance (P<0.1) (Figure 1.1B).  There were also differences in the polyp 
size distribution over time (Figure 1.1C) that were consistent with disease development; 8 
and 12 wk old mice showed the greatest number of small polyps (P<0.05), 16 wk old 
mice had the greatest distribution of medium polyps (P<0.05), and large polyps were 
most abundant at 16 and 20 wks (P<0.05).   
3.2 Tissue expression of inflammatory markers.  Gene expression of inflammatory 
markers (MCP-1, IL-1β, IL-6 & TNF-α) were examined in regions 2 and 3 of the 
intestines of Apc
Min/+
 over time (Figure 1.2).  Regions 2 and 3 were chosen so as to 
represent a section of the intestine with low and high polyp incidence, respectively.  All 
data was normalized to fold-increase from age-matched wildtype mice.   
MCP-1: MCP-1 was elevated at 16 and 20 wks in both sections 2 and 3 (~ 20-35 fold) 
(P<0.05) and there was further elevation at 20 wks in section 2 only (P<0.05) (Figure 
1.2A).   
IL-1β:   In both sections 2 and 3, there was an increase in IL-1β at 12, 16 and 20 wks (~ 
4-10 fold) (P<0.05) and an additional increase was observed at 16 and 20 wks (P<0.05) 
(Figure 1.2B).   
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IL-6: IL-6 was significantly elevated at 16 and 20 wks in section 2 (~ 15-30 fold) 
(P<0.05), and at 12, 16 and 20 wks in section 3 (~ 10-30 fold) (P<0.05).  The greatest 
magnitude of IL-6 expression was observed at 16 wks in both sections (P<0.05) (Figure 
1.2C).   
TNF-α: In sections 2 and 3, TNF-α expression was increased at 12, 16 and 20 wks (~ 4-6 
fold) (P<0.05) (Figure 1.2D).   
3.3 Tissue concentration of inflammatory markers.  The concentration of pro-
inflammatory cytokines (IL-1β, IL-6 and TNF-α) and MCP-1were examined in regions 2 
and 3 of the intestines of Apc
Min/+
at 8, 12, 16 and 20 wks of age (Figure 1.3).  The data 
was normalized to fold-increase from age-matched wildtype mice.   
MCP-1: In section 2, MCP-1 was increased at 16 and 20 wks (~ 3-4 fold) (P<0.05) and in 
section 3 at 12, 16 and 20 wks (~ 5-7 fold) (P<0.05) and there was further elevation at 20 
wks (P<0.05) in both sections (Figure 1.3A).   
IL-1β:   In section 2, IL-1β was increased at 20 wks (~ 1.5 fold) (P<0.05), and in section 
3 at 12, 16 and 20 wks (~ 2 fold) (P<0.05) (Figure 1.3B).    
IL-6: There were no differences in protein concentration of IL-6 across age in section 2.  
However, in section 3, IL-6 concentration was increased at 12, 16 and 20 wks (~ 2-3 
fold) (P<0.05) (Figure 1.3C).    
TNF-α: Similar to IL-6 there were no differences in protein concentration of TNF-α 
across age in section 2.  In section 3, there was an increase in TNF-α only at 12 wks (~ 4 
fold) (P<0.05) (Figure 1.3D).      
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3.4 Plasma MCP-1.   Plasma concentration of MCP-1, a measure of systemic 
inflammation, was also measured in Apc
Min/+
 mice and wildtype mice over time (Figure 
1.4).   MCP-1 was significantly increased in Apc
Min/+
 at 12, 16 and 20 wks (P<0.05) and 
there was an additional increase at 20 wks (P<0.05).   
3.5 Correlations. In order to further address the relationship between polyp progression 
(overall polyp number & abundance of large polyps) and inflammatory mediators we 
performed correlation analyses.  Mice from all time-points were included in these 
analyses.  Figure 1.5 shows the relationship between large polyp number and mRNA 
expression of MCP-1, IL-1β, IL-6 and TNF-α in section 3 of the intestines.  All four 
inflammatory mediators were positively associated with the number of large polyps 
(P<0.01); MCP-1 showed the strongest correlation (R
2
=0.721; Figure 1.5A) followed by 
IL-1β (R
2
=0.659; Figure 1.5B), IL-6 (R
2
=0.566; Figure 1.5C) and TNF-α (R
2
=0.398; 
Figure 1.5D). This was generally consistent with the relationship observed between these 
mediators and the abundance of large polyps in section 2 (P<0.001) and overall polyp 
number in sections 2 and 3 (P<0.001) (data not shown). Similarly, there were positive 
correlations for protein concentration of pro-inflammatory mediators and polyp 
progression (P<0.05) (data not shown) although this relationship was not as strong as that 
observed for gene expression.     
DISCUSSION 
Epidemiological evidence links colon cancer to chronic intestinal inflammation 
(54).  Further support for a role of inflammation in colon cancer comes from studies 
using mouse models that have been shown to be responsive to treatment with anti-
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inflammatory agents, including both anti-inflammatory dietary supplements as well as 
non-steroidal anti-inflammatory drugs (NSAIDs) (39).  Despite this, the timing and 
magnitude of the inflammatory cytokine response in relation to tumorigenesis has not 
been characterized.  This study used an established mouse model of intestinal 
tumorigenesis to examine this response in the Apc
Min/+
 mouse.  Our findings indicate that 
an elevation in the intestinal inflammatory cytokine (MCP-1, IL-1β, IL-6 and TNF-α) 
response occurs at12 wks of age in association with the rapid increase in polyp number.  
Further elevations in these mediators with age were associated with increased polyp size.  
In fact, all inflammatory mediators were positively correlated with the abundance of large 
polyps as well as overall polyp number (data not shown).  These data also generally show 
a greater increase in the cytokine response in intestinal section 3, a region of high polyp 
incidence, compared to section 2 that is considered a region of relatively low polyp 
incidence (55).  These findings contribute to the growing evidence on the association 
between inflammatory cytokines and colon cancer and provide important new data on the 
magnitude and timing of this response in relation to tumorigenesis in the Apc
Min/+
 mouse.    
 The Apc
Min/+
 mouse model has been the most widely used genetically engineered 
model for cancer studies that involve the gastro-intestinal tract.  In fact over 600 articles 
have been published using this model.  It has been shown to be responsive to treatment 
with anti-inflammatory agents, including both anti-inflammatory dietary supplements as 
well as non-steroidal anti-inflammatory drugs (NSAIDs) (39).  For example, Greenspan 
et al. reported that the NSAID Sulindac can decrease intestinal polyp number in the 
Apc
Min/+
 mouse that is associated with a decrease in proliferative and inflammatory 
prostaglandins in the small intestine and colon (56).   Similarly, another study reported 
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that Celecoxib reduced the formation of intestinal polyps that was associated with lower 
levels of COX-2 activity (57).  And we have shown that the anti-inflammatory dietary 
component curcumin can offset intestinal inflammatory cytokines and tumorigenesis in 
this mouse model (52); a decrease in mRNA expression of IL-1β, IL-6, TNF-α and MCP-
1 as well as protein concentration of IL-1β and MCP-1 was observed in the intestines 
following 14 wks of curcumin treatment.   Another study reported that the dietary 
component Silibinin can decrease intestinal tumorigenesis in the Apc
Min/+
 mouse in 
association with a decreased expression of TNF-α, IL-1β but not MCP-1.   However, the 
timing and magnitude of the intestinal pro-inflammatory response in relation to tumor 
progression in this model has not been characterized.  This is surprising given the 
preponderance of studies that have used this model to test anti-inflammatory agents (39).   
Most studies have focused on the effects of various anti-inflammatory treatments over the 
life-span of these mice without consideration for the temporal sequence of inflammation 
in relation to cancer.  To our knowledge there is only one study that has examined any 
inflammatory mediators in the Apc
Min/+
 mouse over time.  Kettunen et al., (2003) 
examined the intestinal immune response in Apc
Min/+
 mice at 5, 8 and 15 wks of age and 
reported an increase in prostaglandin E2 (PGE2) at 15 wks but not TNF-α or IL-12 (58).   
However, MCP-1, IL-6 and IL-1β were not measured in this study and there were no 
attempts made to measure gene expression of any inflammatory mediators.      
 We show here for the first time the timing and magnitude of the inflammatory 
cytokine response in intestinal tissue across time in the Apc
Min/+ 
mouse.  In addition to the 
inflammatory cytokines that have well documented effects on tumor progression (1-5), 
MCP-1 was examined as it has been identified as a major chemokine for macrophage 
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recruitment in several human tumors including the colon (59, 60) and has been associated 
with increased inflammation and tumor grade in various cancers (8, 9).  Our data show an 
increased mRNA expression of MCP-1, IL-1β, IL-6 and TNF-α that is evident at 12 wks 
of age and is consistent with the increase in polyp number that occurs at this time; total 
polyp number (sections 1, 4 and 5) increases from 26 ± 3 at 8 wks to 60 ± 6 at 12 wks.   
Any further increases in the inflammatory response appear to be associated with a change 
in polyp size; 12 wk old Apc
Min/+
 mice had the largest number of small polyps (<1mm) 
whereas 20 wk old mice had the greatest number of large polyps (>2mm).  In fact, a 
positive correlation was observed between the abundance of large polyps and all 
inflammatory mediators.  Similarly, protein concentration of these cytokines generally 
follows the same trend.  It is worth noting that section 3, a section of high polyp 
incidence shows a greater magnitude of inflammation than section 2, a section of low 
polyp incidence (55) that provides further evidence for the association between 
inflammation and tumor burden in this model.  Whether the changes in polyp number and 
size that occurs in this model is a result of the elevated inflammatory response or vice 
versa cannot be determined from this investigation.  Future studies are necessary to 
identify whether inflammation is a cause and/or effect of the changes in polyp number 
and size across time in this mouse model.   
 These findings may have important implications for colon cancer.  Firstly, these 
results may contribute to the future development of biomarkers to assess colon cancer 
progression.  The current literature supports a positive relationship between systemic IL-6 
and increasing tumor stages and tumor size, metastasis and decreased survival (61) in 
colon cancer.  Similarly, MCP-1 has been correlated with increased grade of the tumor 
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(9) advanced tumor stage, lymph node involvement (62) and poor prognosis in breast 
cancer (8, 60), but no studies of this nature have been carried out with colon cancer.  
However, our data shows a strong relationship between polyp progression and MCP-1 in 
a mouse model of colon cancer.  Future studies are necessary to fully evaluate the 
potential of these inflammatory cytokines as prognostic indicators for colon cancer.   
Secondly, these data provide important new information that can be used for the 
determination of appropriate timing of effective treatments that can be used in the design 
of future investigations that target inflammatory processes in mouse models of colon 
cancer.  Based on these data it is likely that anti-inflammatory treatments would be more 
effective as a preventive approach (i.e administered before 12 wks) to reduce polyp 
number and an intervention approach (i.e administered after 12 wks) to reduce polyp size 
in this model.  
 In summary, the Apc
Min/+
 mouse is the most widely used model in studies that 
examine the effect of anti-inflammatory treatments including bioactive food components 
and NSAIDs on intestinal tumorigenesis.  Despite this there is very little information on 
the temporal sequence of inflammation in relation to tumorigenesis in this model.  This is 
the first systematic investigation of the timing and magnitude of the inflammatory 
cytokine (IL-1β, IL-6 and TNF-α) and MCP-1 response in the Apc
Min/+
 mouse. These data 
contribute to the growing evidence on the association between inflammation and colon 
cancer and provide important new data that could be used in the development of 





Figure 1.1. Polyp number in the Apc
Min/+ 
mouse at 8, 12, 16 and 20wks of age.  
Differences in (A) total polyp number (B) colon polyp number and (C) polyp size 
distribution were observed over time (n=6-12/group). P<0.05 * greater than 8 wks, # 























































































Figure 1.2. mRNA gene expression of inflammatory mediators in the Apc
Min/+ 
mouse 
at 8, 12, 16 and 20wks of age.  Differences in mRNA gene expression of (A) MCP-1, 
(B) IL-1β, (C) IL-6, and (D) TNF-α were observed in sections 2 and 3 of the intestines 
over time (n=6-12/group).  P<0.05 * greater than 8 wks, # greater than 12 wks, ! greater 


























































































































Figure 1.3. Protein concentration of inflammatory mediators in the Apc
Min/+ 
mouse 
at 8, 12, 16 and 20wks of age.  Differences in protein concentration of (A) MCP-1, (B) 
IL-1β, (C) IL-6, and (D) TNF-α were observed in sections 2 and 3 of the intestines over 
time (n=6-12/group).  P<0.05 * greater than 8 wks, # greater than 12 wks, ! greater than 


























































































































Figure 1.4. Plasma MCP-1 is increased in the Apc
Min/+ 
mouse model of intestinal 
tumorigenesis. Wildtype and Apc
Min/+ 
mice were sacrificed at various time-points (8, 12, 
16 or 20 wks) and plasma was analyzed for MCP-1 concentration using ELISA.  * MCP-
1 was increased at 12, 16 and 20 wk versus WT (P<0.05).  P<0.05 * greater than 8 wks 



























Figure 1.5. Inflammatory mediators are positively correlated with polyp progression 
in the Apc
Min/+ 
mouse.  Correlations were performed between abundance of large polyps 
and mRNA expression of MCP-1 (A), IL-1β (B), IL-6 (C) and TNF-α (D) in section 3 of 
the intestines.  All inflammatory mediators showed a positive relationship with 
abundance of large polyps (P<0.01). 
 



















































































































LINKING TUMOR ASSOCIATED MACROPHAGES, INFLAMMATION, AND INTESTINAL 
TUMORIGENESIS: ROLE OF MCP-1
2
                                                          
2 McClellan, J.L.,Davis, J.M., Steiner, J.L., Enos, R.T., Jung, S.H., Carson, J.A., Pena, 
M.M., Carnevale, K.A., Berger, F.G., Murphy, E.A. Linking tumor-associated 
macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1. Am J 
Physiol Gastrointest Liver Physiol. 303(10): p. G1087-95.  Reprinted here with 




Tumor associated macrophages are associated with poor prognosis in certain 
cancers.  Monocyte chemoattractant protein 1 (MCP-1) is thought to be the most 
important chemokine for recruitment of macrophages to the tumor microenvironment.   
However, its role on tumorigenesis in a genetic mouse model of colon cancer has not 
been explored.  We examined the role of MCP-1 on tumor associated macrophages, 






 or wildtype 
mice were sacrificed at 18 wks of age and intestines were analyzed for polyp burden, 
apoptosis, proliferation, β-catenin, macrophage number & phenotype, markers for 
cytotoxic T lymphocytes (CTLs) and regulatory T cells (Tregs), and inflammatory 
mediators.  MCP-1 deficiency decreased overall polyp number by 20% and specifically 
large polyp number by 45% (P<0.05).  This was consistent with an increase in apoptotic 
cells (P<0.05), but there was no change detected in proliferation or β-catenin.  MCP-1 
deficiency decreased F4/80 positive cells in both the polyp tissue and surrounding 
intestinal tissue (P<0.05) as well as expression of markers associated with M1 (IL-12 & 
IL-23) and M2 macrophages (IL-13, CD206, TGFβ & CCL17) (P<0.05).  MCP-1 
knockout was also associated with increased CTLs and decreased Tregs (P<0.05).  In 
addition, MCP-1
-/-
 offset the increased mRNA expression of IL-1β & IL-6 in intestinal 
tissue and IL-1β & TNF-α in polyp tissue (P<0.05), and prevented the decrease in SOCS1 
expression (P<0.05).  We demonstrate that MCP-1 is an important mediator of 
tumorgrowth and immune regulation that may serve as an important biomarker and/or 





There is a well-established association between inflammation and cancer risk.  In 
fact, inflammation has been suggested to represent the 7
th
 hallmark of cancer (63).  It has 
been linked to every step involved in the development and progression of colon cancer, 
including cellular transformation, promotion, survival, proliferation, invasion, 
angiogenesis, and metastasis (1, 4).  Macrophages have recently emerged as major 
players in the connection between inflammation and cancer (14, 15); they represent up to 
50% of the tumor mass and produce a wide array of inflammatory mediators with pro-
tumoral functions (14, 15).   Further, they have been associated with alterations in 
adaptive immune responses within the tumor microenvironment that may lead to reduced 
immune surveillance (14, 64).  In general, high levels of tumor associated macrophages 
(TAMs) are associated with poor prognosis in colon cancer (14-18).  Therefore, 
identifying strategies to alter the responses of TAMs may have important implications for 
the progression of colon cancer.   
Monocyte chemoattractant protein 1 (MCP-1), also known as chemokine (C-C 
motif) ligand 2 (CCL2), has been identified as an essential chemokine for monocyte 
trafficking (19-21).  Using targeted gene disruption Lu et. Al (1998) created an MCP-1 
deficient mouse and documented that MCP-1 is uniquely essential for monocyte 
recruitment in several inflammatory models (20).  More recently in cancer models, MCP-
1 has been suggested to be the most important chemokine for macrophage recruitment to 
the tumor microenvironment (22); both rodent and clinical studies have associated MCP-
1 levels with TAM abundance and subsequent cancer progression (23-25).  For example, 





mouse model of intestinal tumorigenesis (65).  Similarly, Bailey et al. has reported that 
MCP-1 expression is associated with TAM number and stage of colorectal cancer in 
humans (24).   Further, in a model of colitis-associated colon cancer it has been reported 
that mice deficient for an MCP-1 specific receptor have less macrophage infiltration, 
reduced COX-2 expression, and decreased tumor size (25).  However, the specific role of 
MCP-1 on macrophage number and phenotype, inflammatory processes, and tumor 
progression in a genetic mouse model of colon cancer has yet to be determined.  
The purpose of this study was to examine the role of MCP-1 on macrophage 
number and phenotype (M1 & M2), markers for certain T cell subsets including cytotoxic 
T lymphocytes (CTLs) and regulatory T cells (Tregs), and selected inflammatory 
mediators (IL-1β, IL-6 TNF-α & SOCS1) in the intestines and the tumor 
microenvironment in a genetic mouse model of intestinal tumorigenesis, and further, to 
relate these to tumor progression (polyp number and size).  This was done by crossing the 
Apc
Min/+ 
mouse, the most widely used genetic mouse model for cancer studies that 
involve the gastro-intestinal tract (38, 39), with an MCP-1 knockout mouse to develop an 
MCP-1 deficient model of intestinal tumorigenesis.  Apc
Min/+ 
mice are heterozygotes for a 
mutation in the adenomatous polyposis coli (Apc) gene and spontaneously develop 
intestinal and colon adenomas.  Since the Apc gene is mutated in a large percentage of 
human colon cancer cases, this is a common model for studying factors that may 
influence progression of colon cancer.  We hypothesized that MCP-1 deficiency would 
reduce macrophage number in the tumor environment and that this would be associated 
with a decrease in inflammation, and a reduction in polyp burden. 
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In this report, we demonstrate that MCP-1 plays a necessary role in macrophage 
recruitment, immune regulation, inflammation, and polyp burden in colon cancer.  MCP-
1 deficiency reduced macrophage number, altered markers of CTLs and Tregs, and 
prevented the increased mRNA expression of inflammatory cytokines in the tumor 
microenvironment that was associated with a reduction in overall polyp number and an 
increase in apoptosis.    
MATERIALS AND METHODS 




 mice on a C57BL/6 background were originally 







) were bred in the University of South Carolina’s Center for Colon 
Cancer Research (CCCR) Mouse Core Facility.  Specifically, Apc
Min/+
 male mice were 
bred with female C57BL/6 mice to generate Apc
Min/+
 mice.  Offspring were
 
genotyped as 
heterozygotes by RT-PCR for the Apc gene by taking
 
tail snips at weaning. The primer 
sequences were sense: 5’-TGAGAAAGACAGAAGTTA-3’;
 
and antisense: 5’-




 mouse was generated by 
introducing MCP-1
-/-
 into the Apc
Min/+





 mice with female MCP-1
-/-
 mice.   Offspring were
 
genotyped for 
the mutant Apc allele as described above and for MCP-1. The primer sequences for MCP-
1 were as follows: mutant GCCAGAGGCCACTTGTGTAG, wild type forward 







 and wild type (n=10/group) mice were maintained on a 
12:12h light-dark cycle in a low-stress environment (22
o
C, 50% humidity and low noise) 
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and provided food and water ad libitum.  All animal experimentation
 
was approved by the 
University of South Carolina’s Institutional
 
Animal Care and Use Committee.  
2.2 Tissue Collection.  Body weight was measured prior to sacrifice (18 wks of age).  
Mice were sacrificed for tissue collection as previously described (65).  Sections 1 and 4 
of the small intestine and the large intestine (section 5) were fixed in 10% buffered
 
formalin (Fisher Scientific, Pittsburg, PA) for 24 h.  For intestinal section 3, polyps were 
excised and mucosal scrapings were performed in TRIzol reagent (Invitrogen, Carlsbad, 
CA).  Samples were stored at –80°C until analysis for macrophage phenotype, T cell 
markers, and inflammatory mediators. Previously reported findings from our laboratory 
has shown that intestinal section 3, a region of high polyp incidence, has a larger 
inflammatory response than section 2, an area of low polyp occurrence (65), and 
therefore we included only section 3 for these analyses.  Blood was collected from the 
inferior vena cava using a heparinized syringe.  Blood parameters were examined 
immediately using a Vetscan blood analyzer (Abaxis, Union City, CA).  The remaining 
blood was spun in a microcentrifuge at 4,000rpm for 15 min.  Plasma was then stored at –
80
o
C until assayed for IL-6 (R&D Systems, Minneapolis MN).   
2.3 Polyp Counts. Formalin-fixed intestinal sections from all animals were rinsed
 
in 
deionized water, briefly stained in 0.1% methylene blue,
 
and counted by the same 
investigator who was blinded to the
 
treatments.  Polyps were counted under a dissecting 
microscope and were categorized according to size (>2 mm, 1–2 mm, and <1 mm).   
2.4 Immunohistochemistry. Intestinal sections were processed to identify apoptotic 
positive cells, proliferating cells, β-catenin and macrophage number. Formalin-fixed, 
paraffin-embedded intestinal sections were Swiss-rolled and cut on a microtome in 4-µm 
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sections.  Apoptotic cells were detected by terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) assay as per the manufacturer’s instructions 
(Apo-Tag kit, Millipore, Billerica, MA).  For proliferation, slides were stained using 
Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA).  Antigens were 
unmasked using proteinase K (Millipore, Billerica, MA) and peroxidase activity was 
inhibited using BLOXALL (Vector Laboratories, Burlingame, CA) for 10 min.  Sections 
were incubated with rabbit polyclonal PCNA antibody (1:200; Abcam, UK) for 1 h at 
RT.   For β-catenin and macrophage staining the HRP-DAB Cell and Tissue staining kit 
(R&D Systems, Minneapolis, MN) was used according to the manufacturer’s 
instructions.  Sections were incubated with rat monoclonal F4/80 (1:50; Serotec, Raleigh, 
NC) and rabbit polyclonal β-catenin (1:100; Santa Cruz Biotechnology, Santa Cruz, CA) 
antibodies for 2 h at RT. Color detection was visualized by exposing sections to 3,3´-
diaminobenzidine (DAB).  TUNEL positive cells, PCNA positive cells and β-catenin 
were visualized using the DAKO Chromavision Systems ACIS 3 system (66).  The 
threshold for positive staining was chosen by the user for automated scoring.  Polyps 
were outlined for qualitative analysis and the percentage of each polyp that met the 
positive staining threshold was averaged for each sample.  Data was then normalized to 
fold change from Apc
Min/+
 mice.  To quantify macrophages, F4/80 positive cells within 
each polyp (positive cells/μm
2
) and villi (10 villi/mouse) were counted (40X 
magnification) and averaged for each animal (67-69).  
2.5 mRNA Gene Expression.  Quantification of gene expression for macrophage 
phenotype (IL-12 & IL-23 (M1 macrophage phenotype), IL-13, CD206, TGF-β & 
CCL17 (M2 macrophage phenotype)), T cell makers (CD8 & Foxp3), and inflammatory 
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mediators (IL-1β, IL-6, TNF-α, SOCS1 (suppressor of cytokine signaling 1)) were 
performed as previously described (65, 70).  Briefly, mucosal tissue and polyps were 
homogenized under liquid nitrogen with a polytron, and total RNA was extracted using 
TRIzol reagent (Invitrogen, Carlsbad CA).  RNA was reverse transcribed into cDNA and 
quantitative RT-PCR analysis was done per manufacturer’s instructions (Applied 
Biosystems, Foster City CA) using TaqMan
®
 Gene Expression Assays. Quantification of 
cytokine gene expression was calculated using the ΔΔCT method.  
2.6 Statistical Analysis.  Analysis was done using commercially available software 







 (polyp burden, apoptosis, proliferation, β-catenin, macrophage number, and gene 
expression in the polyps) a t-test was performed.  When the wild type group was included 
in the analysis (body weight, gene expression in the mucosal tissue, and blood 
parameters) a one-way ANOVA with Student Newman-Keuls post-hoc analysis was 
performed.  Statistical significance was set with an alpha value of P<0.05. Data are 
presented as mean (±SEM). 
RESULTS 
3.1 Body Weight.  Previous published data from our group has shown that Apc
Min/+
 mice 
develop cachexia that is positively correlated with polyp burden (7).  As expected 
Apc
Min/+
 mice show a decrease in body weight compared to wild type mice (22.2 ± 0.4 




had an average body weight of 25.6 ± 0.6 that was not different from wild type mice.   












sections.  Overall polyp number (sections 1, 4 and 5) was 




 (42.8 ± 3.0 versus 54.2 ± 2.5) (P<0.05) (Figure 
2.1A).  To examine polyp size (Figure 2.1B), we classified polyps as being large (> 1mm 
in diameter), medium (<2 > 1 mm in diameter) or small (< 1 mm in diameter).  
Interestingly, we found that the difference in overall polyps between the groups can be 





had 45% fewer large polyps than Apc
Min/+
mice (16.4 ± 5.0 versus 29.9 ± 1.4) (P<0.05) 
but there were no significant differences in the number of small or medium polyps.  We 





 by ~40% in section 1 (3.3 ± 0.5 versus 5.6 ± 0.5) 
(P<0.05), ~15% in section 4 (37.7 ± 2.7 versus 45.1 ± 2.6), and ~45% in section 5 (colon) 
(1.8 ± 0.4 versus 3.4 ± 0.6) (P<0.05).       
3.3 Apoptosis.  Apoptosis, or programmed cell death, is typically evaded by tumors and 
leads to uncontrolled tumor growth (71).  TUNEL staining was used to localize apoptotic 
cells within polyps (Figure 2.2A).  This analysis was done only in section 4, a region of 
high polyp incidence, in order to examine the largest number of polyps possible.  MCP-1 
deficiency increased the number of TUNEL-positive cells (P<0.05); after normalizing the 
Apc
Min/+
 group to 1.0 we found a 3.3 fold increase in the percentage of the polyp area 




 mice (P<0.05).   
3.4 Proliferation. Sustaining proliferative signaling is one of the hallmarks of cancer.  
PCNA staining was done in section 4 to quantify proliferating cells (Figure 2.2B). There 
were no differences detected in the percentage of the polyp area staining positive for 






 mice, respectively).  
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3.5 β-catenin.  Immunohistochemical staining for β-catenin, a central molecule of the 
Wnt-signaling pathway that is involved in cellular replication and which has been 
correlated with poor prognosis in colon cancer was also performed (67-69).  This analysis 
was also done in section 4 to allow for examination of the largest number of polyps 
possible.  We did not detect a difference in the percentage of polyp area staining positive 







respectively) (Figure 2.2C).  
3.6 Macrophage Number & Phenotypic Markers. Immunohistochemistry using F4/80 
antibody was used to identify macrophages in section 4 of the intestine.  F4/80-positive 
cells were counted within the villus (Figure 2.2D) (10 villi were counted per mouse) as 
well as the polyps (Figure 2.2E) (positive cells/μm
2
) and averaged per animal.  We found 





 mice (23.7 ± 2.6 versus 31 ± 2.5) (P<0.05).  Similarly, F4/80 positive 




 mice (53.6 ± 8.1 versus 
92.2 ± 7.4) (P<0.05).  Further, gene expression of macrophage phenotypic markers (IL-
12 & IL-23 (M1 macrophage phenotype), IL-13, CD206, TGF-β and CCL17 (M2 
macrophage phenotype)) were examined in the mucosal scrapings (Figure 2.3C) of 
intestinal tissue and in the polyps (Figure 2.3D).  For mucosal scrapings, data was 
normalized to fold-change from age-matched wild type mice and for polyps, to fold-
change from Apc
Min/+
 mice.  In the mucosal tissue, there was an increase in mRNA 
expression of IL-23, IL-13, CD206 and CCL17 in the Apc
Min/+ 
mouse (P<0.05) and MCP-
1 deficiency blunted this response (P<0.05).  Similarly, in the polyps, we detected a 
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 mice (P<0.05).   
3.7 T cell Markers.  We also performed gene expression analysis of markers associated 
with CTLs (CD8) and Tregs (Foxp3) (Figure 2.4).  In the mucosal tissue (Figure 2.4A), 
there was no difference in mRNA gene expression of CD8 across the groups.  There was 
however, a significant increase in Foxp3 in the Apc
Min/+ 





group.  For the polyps (Figure 2.4B), we found a significant 




group (P<0.05).  And 





mice (P<0.05).      
3.8 Inflammatory Modifiers.  Gene expression of inflammatory cytokines (IL-1β, IL-6 & 
TNF-α) and SOCS1 was examined in the mucosal scrapings of intestinal tissue as well as 
the polyps (Figure 2.5).  In the mucosal tissue (Figure 2.5A), IL-1β and IL-6 were 
increased in Apc
Min/+ 
mice (P<0.05) and this effect was blunted for IL-6 and completely 
blocked for IL-1β when MCP-1 was depleted (P<0.05). There were no differences in 
TNF-α across the groups.  Consistent with the inflammatory cytokine data, SOCS1 
mRNA expression was decreased in Apc
Min/+ 
mice (P<0.05) but there was no difference 




mice.  In the polyps 





mice (P<0.05) but there were no significant differences detected for IL-







 mice (P<0.05).   
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3.9 Complete Blood Count & Plasma IL-6.    A complete blood count was performed as 
both white blood cell (WBC) and red blood cell (RBC) counts have been shown to be 
altered during progression of intestinal tumorigenesis in this mouse model (Table 2.1) 





1.8) compared to wild type (5.7m/mm
3
 ± 0.6) (P<0.05) and MCP-1 deficiency blunted 
this response (7.1m/mm
3
 ±0.9) (P<0.05).  In general, these findings were consistent 
across all cell types (lymphocytes, monocytes & granulocytes).  For RBCs, Apc
Min/+
 mice 
showed an overall large decrease (2.6m/mm
3
 ± 0.2) versus wild type mice (7.9m/mm
3
 ± 
0.2) (P<0.05) and MCP-1 deficiency offset this effect (3.9m/mm
3
 ± 0.2) (P<0.05).  
Similar results were seen for hematocrit and hemoglobin.  We also examined circulating 
levels of IL-6 in plasma as a marker of systemic inflammation.  Consistent with previous 
findings from our laboratory (7), we confirm an increase in plasma IL-6 in Apc
Min/+
 mice 
(40.0 ± 6.3 ρg/mL) compared to wild type mice (0.8 ± 0.8 ρg/mL) (P<0.05), and report 
that this effect was blunted in the MCP-1 deficient Apc
Min/+
 mice (19.3 ± 1.9 ρg/mL) 
(P<0.05).   
DISCUSSION 
Macrophages play a key role in tumorigenesis; they are a major player in the 
inflammatory response that contributes to cellular transformation, promotion, apoptosis, 
proliferation, invasion, angiogenesis, and metastasis (1, 4, 14, 15, 73, 74).   MCP-1 has 
been identified as the most important chemokine for recruitment of macrophages to the 
tumor microenvironment (22).  However, the link between MCP-1, macrophages, 
inflammation, and tumorigenesis in colon cancer has not yet been established.  Through 




 mouse bred in our laboratory, we report the novel finding 
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that MCP-1 is a link between macrophages, inflammation, and tumorigenesis in colon 
cancer.  MCP-1 deficiency decreased overall polyp number and abundance of large 
polyps that was consistent with an increase in apoptosis.  Overall macrophage number 





 mice.   Further, MCP-1
-/-
 mice had increased expression of CD8 and 
decreased expression of Foxp3 in the tumor microenvironment, markers for CTLs and 
Tregs, respectively.  MCP-1 deficiency also reduced the expression of inflammatory 
cytokines in the intestinal tissue and polyps as well as circulating levels of IL-6.  
Both rodent and clinical studies have associated MCP-1 levels with tumorigenesis 
(23-25).  However, there have been relatively few studies that have specifically linked 
MCP-1 to colon cancer progression.  Here we show that Apc
Min/+
 mice deficient for 
MCP-1 have a reduction in overall intestinal polyp number (~20%) as well as the number 
of large polyps (~45%).  We interpret this to mean that MCP-1 can affect both 
development and growth of polyps.  However, it appears as if it plays a larger role in 
progression of growth as opposed to initiation of development. While the current 
investigation was limited to one sacrifice time-point (18 wks), given that Apc
Min/+
 mice 
develop most of their polyps by 12 wks of age, it is likely that an even larger disparity in 
polyp growth, but not number, would be observed if mice had been sacrificed at a later 
time-point.  These findings are consistent with a recent report from our laboratory 
showing that MCP-1 is correlated with the number of large polyps in this same mouse 
model (65).   And similarly, with a recent rodent study that shows a decrease in the size 
of tumors in an MCP-1 receptor deficient mouse model of colitis-associated colon cancer 
(25).  Further, it has been reported that ablation of D6, a promiscuous decoy receptor that 
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scavenges inflammatory chemokines, increases colitis and results in more severe 
malignancies in colitis-associated cancer (75).  Our findings are also confirmed by  the 
only available clinical study reporting an association between MCP-1 expression and 
stage of colorectal cancer (24).   
In addition to decreased polyp number, MCP-1 deficiency increased apoptosis 
suggesting that MCP-1 knockout may lead to prevention of the dysregulation of apoptosis 
in colon cancer.  While there have been no other reported studies that have examined the 
role of MCP-1 on apoptosis in colon cancer, our findings are supported by recent in vitro 
data in other cancer models.  For example, knock down of MCP-1 has been shown to 
enhance tumor cell apoptosis in mammary carcinoma cells (76) and MCP-1 inhibited 
apoptosis in PC-3M prostate colon cancer cells (77).  However, we did not detect an 
effect of MCP-1
-/- 
on the number of proliferating cells. This is inconsistent with a recent 
report showing a decrease in proliferation in both a breast cancer and prostate cancer 
model following pharmacological inhibition of MCP-1(78).   It is possible that the effects 
of MCP-1 on proliferation may be dependent on the specific cancer model used; to our 
knowledge there are no reports of an effect of MCP-1 on proliferation in colon cancer.   
Similarly, there was no change in β-catenin with MCP-1 knockout.  In contrast, a recent 
study reported less nuclear β-catenin accumulation in an MCP-1 receptor deficient mouse 
model of chronic colitis (25).  However, a different mouse model was used in that 
investigation, which may explain, at least in part, the variability in findings across 
studies.   
In addition to the polyp characteristics, we also examined the role of MCP-1 on 
macrophage number in the tumor environment and surrounding intestinal tissue.  Recent 
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data has shown that MCP-1 has been associated with infiltration of macrophages to the 
tumor microenvironment (22, 23).  These macrophages can represent up to 50% of the 
tumor mass producing a wide array of inflammatory mediators with pro-tumoral 
functions (14, 15).  Further, abundance of TAMs has been associated with poor prognosis 
in colon cancer (14-18, 24).  For example, one study reported a reduction in macrophage 
infiltration that was consistent with a decrease in the size of colon polyps in an MCP-1 
receptor deficient mouse model of colitis-associated colon cancer (25).  Further, in a 
clinical study it was documented that macrophage accumulation within the tumor was 
correlated with stage of progression (24).  Consistent with these reports, our MCP-1 
deficient Apc
Min/+
 mice have decreased macrophage number in both the polyps and 
surrounding intestinal tissue.  Because it is now well accepted that macrophages 
constitute an extremely heterogeneous population that is divided into two main classes 
(M1 and M2) (14), we also examined the role of MCP-1 on expression of M1 and M2 
phenotypic markers.  In general, it is thought that M1 macrophages are cytotoxic against 
neoplastic cells, whereas M2 macrophages exert pro-tumoral functions (14).  We report 
the novel finding that MCP-1 deficiency reduces the expression of both M1 (IL-12 and 
IL-23) and M2 (IL-13, CD206, TGF-β and CCL17) macrophage phenotypic markers in 
the tumor environment as well as surrounding intestinal tissue in the Apc
Min/+
 mouse 
model of colon cancer.  While our data suggests that a reduction in both M1 and M2 
macrophages is associated with better prognosis in colon cancer, a greater understanding 
of the roles of these macrophage subsets within the tumor microenvironment is 
necessary.    
41 
 
It is well recognized that CTLs constitute one of the most important effector 
mechanisms of anti-tumor immunity (33, 34).  For example, adoptive transfer of CD8+ 
cells has been show to control the growth of B16 melanoma in mice (35).  On the other 
hand, Tregs have been associated with accelerated tumor growth and immune evasion 
through their inhibitory actions on CTLs and helper T cells (36, 37).  To date, there is 
very little evidence on the relationship between MCP-1, macrophages and T cell 
responses in colon cancer.  We examined the role of MCP-1 on markers associated with 
CTLs (CD8) and Tregs (Foxp3).  Our findings illustrate a regulatory role of MCP-1 on 
expression of CD8 and Foxp3 in colon cancer; MCP-1 deficiency increased expression of 
CD8 in the polyps and decreased expression of Foxp3 in the mucosal tissue and polyps.  
Our results are consistent with previously reported data showing that blockade of MCP-1 
can result in activation of CTLs in a mouse model of lung cancer and a reduction in Tregs 
in TC1 tumor-bearing mice (79, 80).  These findings should be substantiated using 
fluorescence activated cell sorting methodology to firmly establish a role of MCP-1 on 
immune regulation in the tumor microenvironment.  
The inflammatory cytokines IL-1β, IL-6, and TNF-α have been associated with 
poor outcome in colon cancer (1, 4).  It has been proposed that the mutual interaction of 
macrophages with cancer cells enhances production of inflammatory cytokines that 
transform the tumor microenvironment so that it favors the survival, growth and motility 




 mice is the first to report that 
a reduction in macrophage number corresponds to a reduction in the inflammatory 
cytokine response in the tumor environment as well as circulating IL-6 in a mouse model 
of colon cancer.  We also examined expression of SOCS1, an important negative 
42 
 
physiological regulator of cytokine responses.  A recent study reported spontaneous 
colorectal carcinoma development and nuclear β-catenin accumulation in SOCS1 
deficient mice suggesting its role as an anti-oncogene that prevents inflammation-
mediated carcinogenesis (82).   Our data show a reduction in SOCS1 expression in the 
polyps and surrounding intestinal tissue in Apc
Min/+
 mice that is eliminated when MCP-1 
is knocked down.  This finding suggests that MCP-1 plays a role in dysregulation of 
cytokine signaling through silencing of SOCS1.  It is important to point out that we did 
not distinguish between macrophage-mediated inflammation and inflammation facilitated 
by the tumor cells themselves; it is likely that MCP-1 regulates inflammation in both cell 
types (83).  It is also important to note that only mRNA gene expression of these 
inflammatory markers was measured in this study. However, a recent study from our 
laboratory shows that mRNA expression of several of these same inflammatory 
mediators is mirrored by elevations in protein concentrations (65).    
Changes in both WBC and RBC counts are characteristic in colon cancer and 
have been show to occur in the Apc
Min/+
 mouse (72).  We therefore also performed a 
complete blood count to determine the role of MCP-1 on these parameters in the Apc
Min/+
 
mouse.  In general, our data show that MCP-1 deficiency prevents the overall increase in 
WBCs as well as the increase in specific subsets including lymphocytes, monocytes and 
granulocytes.  Similarly, the decrease in RBCs, hematocrit and hemoglobin that occurs in 
the Apc
Min/+
 mouse is offset when MCP-1
-/-
 is knocked out.   
In summary, we report that MCP-1 is an important regulator of macrophages, T 
cells, and inflammatory responses in the tumor microenvironment that can lead to 
increased polyp burden in the Apc
Min/+







 mouse that we developed in our laboratory, we show a decrease in 
overall polyp number and large polyp abundance that was consistent with a reduction in 
macrophage number, an alteration in T cell markers that are associated with improved 
immune surveillance, and a decrease in inflammatory processes in the polyp tissue and 
surrounding intestinal tissue as compared to MCP-1 sufficient Apc
Min/+
 mice. Given the 
important regulatory role of MCP-1 in these facets of cancer, development of effective 
pharmacological or antibody approaches to inhibit MCP-1 may have important 
implications for the prevention and/or treatment of colon cancer.
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Table 2.1. Circulating levels of white blood cells, red blood cells, and IL-6 are 
altered in Apc
Min/+ 
mice deficient for MCP-1. Values are means ± SEM. Data are 
representative of three experimental blocks. * significantly different from wild type 
(P<0.05), # significantly different from Apc
Min/+ (
P<0.05), ** trend to be different from 
wild type (P<0.1), and ## trend to be different from Apc
Min/+
 (P<0.1).   
  WT MIN MIN/MCP 
WBC (m/mm3) 5.7 ± 0.58 13.6 ± 1.88 * 7.1 ± 0.89 # 
Lym (m/mm3) 4.4 ± 0.43 11.3 ± 1.61 * 5.9 ± 0.75 # 
Mon (m/mm3) 0.20 ± 0.01 0.25 ± 0.02 0.16 ± 0.02 # 
Gra (m/mm3) 1.2 ± 0.16 1.7 ± 0.24 ** 0.94 ± 0.10 # 
RBC (m/mm3) 7.9 ± 0.16 2.6 ± 0.22 * 3.9 ± 0.18 * # 
Hct (%) 34.9 + 1.17 14.6 + 0.84 * 20.0 + 1.2 * # 
Hb (g/dL) 12.2 + 0.25 3.9 + 0.33 * 6.4 + 0.33 * # 




Figure 2.1. MCP-1 deficiency reduces tumorigenesis in the Apc
Min/+ 
mouse.  







 (n=10/group) mice at 18 wks of age. Values 
are means ± SEM. Data are representative of three experimental blocks. * significantly 












































































Figure 2.2. MCP-1 deficiency increases the number of apoptotic cells and decreases 
macrophage number but does not affect proliferation or β-catenin. TUNEL-positive 







 mice (n=10/group) at 18 wks of age (A).   Polyps were stained for 






 mice (n=10/group) (B). β-catenin 







(n=10/group) (C). The number of F4/80 positive cells was counted in the villi (D) and 






mice (n=10/group).  
Values are means ± SEM. Data are representative of three experimental blocks. * 




Figure 2.3. Macrophage number and expression of M1 and M2 phenotypic markers 
are reduced in Apc
Min/+ 
mice deficient for MCP-1.   RT-PCR was performed to 
determine mRNA gene expression of macrophage phenotypic markers in the mucosal 







wild type mice (mucosal scrapings only) (n=10/group) at 18 wks of age.  Values are 
means ± SEM. Data are representative of three experimental blocks. * significantly 
































































Figure 2.4. MCP-1 deficiency alters markers associated with CTLs and Tregs in 
Apc
Min/+ 
mice.  RT-PCR to determine mRNA gene expression of CD8 and Foxp3 was 







 and wild type mice (mucosal scrapings only) (n=10/group) at 18 wks 
of age. Values are means ± SEM. Data are representative of three experimental blocks. * 
























































Figure 2.5. MCP-1 knockout alters the inflammatory response in Apc
Min/+ 
mice.  RT-
PCR to determine mRNA gene expression of IL-1β, IL-6, TNF-α, and SOCS1 was 







 and wild type mice (mucosal scrapings only) (n=10/group) at 18 wks 
of age. Values are means ± SEM. Data are representative of three experimental blocks. * 






























































EXERCISE EFFECTS ON POLYP BURDEN AND IMMUNE MARKERS IN THE APC
MIN/+ 
MOUSE 
MODEL OF INTESTINAL TUMORIGENESIS
3 
                                                          
3 McClellan, J.L.,Steiner, J.L., Day, S.D., Enos, R.T., Davis, J.M., Singh, U.P., Murphy, 
E.A.  Exercise effects on polyp burden and immune markers in the ApcMin/+ 
mouse model of intestinal tumorigenesis. Int J Oncol. 45(2): p. 861-8.  Reprinted 





Many observational epidemiologic studies suggest an association between 
exercise and colon cancer risk. The mechanisms contributing to a preventative effect of 
exercise on colon cancer are complex and multifaceted.  Altered immune system function 
is one possible mechanism that has been largely unexplored.  Therefore, the purpose of 
this study was to examine the effects of exercise on markers associated with macrophages 
and select T cell populations in a mouse model of intestinal tumorigenesis and to relate 
this to polyp characteristics.  Male Apc
Min/+
 mice were randomly assigned to either 
sedentary (Sed) or exercise (Ex) treatment (n=6-9/group).  The exercise treatment 
consisted of treadmill running for 1hr/day and 6 days a wk at 15m/min from 4wks of age 
until 16 wks of age.  Intestinal polyps were counted and categorized by size. Mucosal 
tissue was analyzed for mRNA expression of overall macrophages (F4/80), for genes 
associated with M1 (IL-12, IL-23, & Nos2) and M2 (CD206, IL-10, IL-4, CCL17, 
CCL22, & Arg-1) macrophages and the macrophage chemoattractants MCP-1, Fetuin A, 
& CXCL14.  Markers for cytotoxic T cells (CTLs) and regulatory T cells were also 
examined by measuring mRNA expression of CD8 and Foxp3, respectively.   While there 
was no significant difference in overall polyp number between the groups (Sed: 23.3 ± 
4.3 and Ex: 16.5 ± 4.3), Ex did have a reduction in the number of large polyps (Sed:6.1 ± 
1.1 and Ex: 3.0 ± 0.6) (P<0.05).  This was consistent with a decrease in spleen weight 
(P<0.05).  Similarly, Ex reduced mRNA expression of overall macrophages (F4/80) as 
well as markers associated with both M1 (IL-12) and M2 (CD206, CCL22, & Arg-1) 
subtypes (P<0.05) but there was no significant decrease in macrophage chemoattractants.  
CD8 expression was increased while Foxp3 expression was decreased with Ex (P<0.05).  
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Overall this data provides important new information on immune regulation as a possible 
mechanism for the documented benefits of exercise training on reducing colon cancer 
progression.   
INTRODUCTION 
Colon cancer remains a significant global health concern; it is the third most 
common malignancy and the fourth most common cause of cancer mortality(42, 43, 84, 
85).  Annually, it accounts for approximately 600,000 deaths worldwide.  However, the 
vast majority (~80%) of these cases can be ascribed to environmental causes and are 
therefore potentially preventable (45).  For instance, physical inactivity has been reported 
to account for 10% of all colon cancer cases (26), whereas physical activity has been 
associated with reduced risk for incidence of colon cancer.  This inverse relationship 
between physical activity and colon cancer risk is supported by epidemiological studies 
as well as controlled experimental studies using rodent models. For example, nine weeks 
of treadmill running has been reported to decrease the total number of intestinal polyps as 
well as the number of large polyps in the Apc
Min/+
 mouse model of intestinal 
tumorigenesis (27). Similarly a recent study in a multiethnic colon cancer screening 
population reported that exercising for one hour per week was associated with a lower 
prevalence of polyps and adenomas when compared to those who exercised less or not at 
all (28).  
The mechanisms responsible for a preventative effect of exercise on colon cancer 
risk are complex and multifaceted.  An exercise-induced alteration in immune system 
function is one possible mechanism that has not been widely explored.  Macrophages, 
cells of the innate immune system, have recently emerged as major components in the 
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development of colon cancer given their ability to produce a wide array of inflammatory 
mediators with pro-tumoral functions (14, 15).  In general, these cells have been 
associated with poor prognosis in colon cancer (14-18, 24).  For example, one study 
reported a reduction in macrophage infiltration that was consistent with a decrease in the 
size of colon polyps in an MCP-1 receptor deficient mouse model of colitis-associated 
colon cancer (25).  Further, in a clinical study it was documented that macrophage 
accumulation within the tumor was positively correlated with stage of progression (24).  
Consistent with these reports, we have documented that MCP-1 deficient Apc
Min/+
 mice 
have decreased macrophage number in both the polyps and surrounding intestinal tissue 
and this was associated with a reduction in total polyp and large polyp number.  Exercise 
has been reported to influence macrophage behavior in various disease models.  For 
instance, it has been shown that exercise can reduce macrophage-mediated inflammation 
in an obese mouse model (29). Similarly, macrophage infiltration associated with the 
reversal of arterial inflammation was decreased by exercise training in aged mice (30). 
However, while it is well established that macrophages play a significant role in the 
pathogenesis of colon cancer and that exercise can influence the macrophage response, 
there is very little evidence on the benefits of exercise on macrophage behavior in the 
presence of colon cancer.  
T cells also play a significant role in tumorigenesis and have been shown to be 
altered by exercise (31, 32).  It is well recognized that cytotoxic T lymphocytes (CTLs) 
constitute one of the most important effector mechanisms of anti-tumor immunity (33, 
34).  For example, adoptive transfer of CD8+ cells controls the growth of B16 melanoma 
in mice (35).  On the other hand, regulatory T cells (Tregs) have been associated with 
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accelerated tumor growth and immune evasion through their inhibitory actions on CTLs 
and helper T cells (36, 37).  The T cell response to exercise has been reported to be 
highly variable and is likely dependent on the mode, intensity and duration of exercise.  
However, to date there is no evidence on the effects of exercise on T cells in a mouse 
model of colon cancer.  
The purpose of this investigation was to examine the effects of exercise on 
expression of markers associated with macrophages and certain T cell subsets in a mouse 
model of intestinal tumorigenesis and to relate this to polyp characteristics.  We used the 
Apc
min/+ 
mouse, the most widely used genetic mouse model for cancer studies that involve 
the gastro-intestinal tract (38). Since the Apc gene is mutated in a large percentage of 
human colon cancer cases, this is a common model for studying factors that may 
influence progression of colon cancer.  The exercise protocol was designed to mimic a 
lifestyle that encompasses daily physical activity; mice were exercised for 1h/day, 6 
days/week, for a 12 week period.  We hypothesized that daily exercise would reduce the 
expression of markers associated with macrophages and alter the T cell expression profile 
in the tumor environment, and that this would be associated with a reduction in polyp 
burden. 
MATERIALS AND METHODS 
2.1 Animals.  Apc
Min/+
 mice on a C57BL/6 background were originally purchased from 
Jackson Laboratories (Bar Harbor, ME).  All experimental mice (Apc
Min/+
) were bred in 
the University of South Carolina’s Center for Colon Cancer Research (CCCR) Mouse 
Core Facility.  Specifically, Apc
Min/+
 male mice were bred with female C57BL/6 mice to 
generate Apc
Min/+
 mice.  Offspring were
 
genotyped as heterozygotes by RT-PCR for the 
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Apc gene by taking
 
tail snips at weaning. The primer sequences were sense: 5’-
TGAGAAAGACAGAAGTTA-3’;
 
and antisense: 5’-TTCCACTTTGGCATAAGGC-3’.  
Male Apc
Min/+
 mice were used in this experiment and were maintained on a 12:12h light-
dark cycle in a low-stress environment (22
o
C, 50% humidity and low noise) and provided 
food (AIN-76A) and water ad libitum. All animal experimentation
 
was approved by the 
University of South Carolina’s Institutional
 
Animal Care and Use Committee.  
2.2 Exercise Protocol.  Male Apc
Min/+
 mice were randomly assigned to either the 
sedentary (Sed; n=9) or exercise (Ex; n=6) treatment.  Mice in the Ex group ran on the 
treadmill at 15m/min and at a 5% incline for 1h per day (starting at 7pm), 6 days per 
week from 4 to 16 weeks of age.  Mice in the Sed group remained in their cages in the 
treadmill room throughout the exercise bouts but were exposed to similar handling and 
noise in an attempt to control for extraneous stresses, and were deprived of food and 
water during the exercise sessions.    
2.3 Tissue Collection.  Body weight was measured weekly from 4 to 16 weeks of age.  
Mice were sacrificed for tissue collection as previously described (65, 86).  Briefly, 
sections 1 and 4 of the small intestine and the large intestine (section 5) were fixed in 
10% buffered
 
formalin (Fisher Scientific, Pittsburg, PA) for 24 h.  For intestinal section 
3, mucosal scrapings were performed in TRIzol reagent (Invitrogen, Carlsbad, CA).  
Samples were stored at –80°C until analysis for the expression of markers associated with 
macrophage phenotype and certain T cell subsets.  Previously reported findings from our 
laboratory have shown that intestinal section 3 has a greater polyp incidence than section 
2 (65), and therefore we included only section 3 for these analyses.  Visceral fat pads 
(retroperitoneal, epididymal, and mesentery) were dissected and weighed for the 
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measurement of total visceral fat as it has been reported that Apc
Min/+
 mice become 
cachectic with disease progression (87).  Spleen was also weighed as splenomegaly has 
been shown to be associated with increased polyp number in this model (86).  Blood was 
collected from the inferior vena cava using a heparinized syringe and blood parameters 
were examined immediately on fresh whole blood using a Vetscan blood analyzer 
(Abaxis, Union City, CA).   
2.4 Polyp Counts. Formalin-fixed intestinal sections from all animals were rinsed
 
in 
deionized water, briefly stained in 0.1% methylene blue,
 
and counted by the same 
investigator who was blinded to the
 
treatments.  Polyps were counted under a dissecting 
microscope and were categorized according to size (>2 mm, 1–2 mm, and <1 mm).   
2.5 mRNA Gene Expression.  Quantification of gene expression for total macrophages 
(F4/80), markers associated with macrophage phenotype (IL-12, IL-23, & Nos2 (M1 
macrophage phenotype), CD206, IL-10, IL-4, CCL17, CCL22, & Arg-1 (M2 macrophage 
phenotype)), macrophage chemoattractants (MCP-1, Fetuin A, & CXCL14), and T cell 
subsets (CD8 & Foxp3) were performed as previously described (65, 70).  Briefly, 
mucosal tissue was homogenized under liquid nitrogen with a polytron, and total RNA 
was extracted using TRIzol reagent (Invitrogen, Carlsbad CA).  The extracted RNA 
(2.5μL of sample) was dissolved in diethyl pyrocarbonate (DEPC)-treated water and 
quantified spectrophotometrically at 260nm wavelength.  RNA was reverse transcribed 
into cDNA and quantitative RT-PCR analysis was done per manufacturer’s instructions 
(Applied Biosystems, Foster City CA) using TaqMan
®
 Gene Expression Assays. 
Quantification of cytokine gene expression was calculated using the ΔΔCT method (88).  
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2.6 Statistical Analysis.  Analysis was done using commercially available software 
(SigmaStat, SPSS, Chicago, IL).  A two-way repeated measures ANOVA was performed 
on body weight measurements.  T-tests were performed on all other data.  Statistical 
significance was set with an alpha value of P<0.05. Data are presented as mean (±SEM). 
RESULTS 
3.1 Body Weight and Visceral Fat Mass. It has been reported that Apc
Min/+
 mice develop 
cachexia that is positively correlated with polyp burden (7).  Therefore, we examined the 
potential benefits of exercise on body weight and visceral fat mass in the Apc
Min/+
 mouse.  
At 15 and 16 weeks of age, there was an apparent difference (~1-2 g) between the groups; 
the Sed group weighed 26.1g ± 1.6 and 25.9g ± 1.4 at 15 and 16 weeks, respectively, 
whereas the Ex group weighed 27.3g ± 0.9 and 27.3g ± 0.9 (P<0.1) (Figure 3.1A). 
However, this did not quite reach statistical significance.  Visceral fat tissue 
(retroperitoneal, epididymal, and mesentery) was collected at sacrifice and weighed to 
determine any influence of exercise on cachexia-related fat mass.  There was no 
protective effect of exercise on total visceral fat pad weight (Sed: 1262.2mg ± 189.2, Ex: 
1471.2mg ±197.7) (Figure 3.1B).   
3.2 Spleen Weight.  Increased spleen weight has been positively associated with polyp 
burden in this model (86).  Therefore, spleens were harvested during sacrifice at 16 
weeks of age, weighed, and expressed relative to body weight. Exercise significantly 
decreased spleen weight versus the Sed group (0.5mg/Kg ± 0.0 versus 0.68mg/Kg ±0.01, 
respectively) (P=0.05) (Figure 3.1C). 
3.3 Complete Blood Count.  A complete blood count was performed at sacrifice as both 
white blood cell (WBC) and red blood cell (RBC) counts have been shown to be altered 
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during progression of intestinal tumorigenesis in this mouse model (Figure 3.2) (86).  





± 0.6) (P=0.07).  Similarly, there was a trend for an exercise-induced 
increase in hematocrit (Hct) compared to Sed (34.6 % ± 2.0 versus 27.1 % ± 3.8) 
(P=0.07).  But there were no apparent differences among the groups for RBCs or 
hemoglobin (Hb).    
3.4 Polyp incidence.   At 16 weeks of age, mice (Sed and Ex) were sacrificed, intestinal 
tissue was harvested and polyps were counted on formalin-fixed, methylene blue-stained
 
sections.  Overall polyp number (sections 1, 4 and 5) was not significantly changed by 
exercise (23.3 ± 4.3 versus 19.2 ± 4.2 for Sed and Ex, respectively) (Figure 3.3A).  To 
examine polyp size (Figure 3.3B), we counted and classified polyps as being large (> 
1mm in diameter), medium (<2 > 1 mm in diameter) or small (< 1 mm in diameter).  
Interestingly, we found a significant reduction in the number of large polyps with 
exercise; the Ex group had 48% fewer large polyps than the Sed group (3.2 ± 0.7 versus 
6.1 ± 1.1) (P<0.05) but there were no significant differences in the number of small or 
medium polyps.  
3.5 Macrophage Number & Phenotypic Markers.  Gene expression of macrophage 
phenotypic markers (IL-12, IL-23 & Nos2 (M1 macrophage phenotype), CD206, IL-10, 
IL-4, CCL17, CCL22 & Arg-1 (M2 macrophage phenotype), were examined in the 
mucosal scrapings (Figure 3.4A) of intestinal tissue.  Data was normalized to fold-change 
from Sed mice.  There was a significant decrease in mRNA expression of F4/80, a 
general macrophage marker (P<0.05).  Similarly, there was a decrease in mRNA 
expression of the M2 associated macrophage markers, CD206, CCL22 and Arg in the Ex 
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mice (P<0.05), and a trend for a decrease in CCL17 (P<0.06).  Even though not all 
markers associated with M2 macrophages were significantly reduced with exercise, all 
were consistently decreased.  IL-12, a marker associated with the M1 macrophage 
phenotype was also decreased in the Ex mice (P<0.05) but there was no change in IL-23 
or Nos2.  Gene expression of macrophage-associated chemokines MCP-1, Fetuin A and 
CXCL14 were also examined in the mucosal scrapings.  While mRNA expression of each 
of these markers was decreased with exercise (Figure 3.4B), statistical significance was 
not reached.    
3.6 Changes in T cell expression.  Given the role of T cell subsets in tumorigenesis, we 
also performed gene expression analysis of markers associated with CTLs (CD8) and 
Tregs (Foxp3) (Figure 3.5).  CD8, a marker for CTLs that represents one of the most 
important effector mechanisms of anti-tumor immunity, was increased with exercise 
(P<0.05).  Conversely, Foxp3, a marker for Tregs that are known to suppress immune 
function and that have been associated with increased tumorigenesis, was decreased with 
exercise (P<0.05).  
DISCUSSION 
There is an inverse relationship between physical activity and colon cancer risk 
(89).  A multitude of mechanisms, including immune function dysregulation, have been 
implicated in this response. Macrophages and T cells play a significant role in the 
pathogenesis of colon cancer and exercise can influence the actions of these cells; 
however, there is very little evidence on the benefits of exercise on macrophage and T 
cell responses in the settings of colon cancer. We examined the effects of exercise on 
markers associated with macrophages and select T cell subsets in a mouse model of 
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intestinal tumorigenesis in relation to polyp characteristics.  Overall, certain markers 
associated with both the M1 and the M2 macrophage phenotype were reduced in Apc
Min/+
 
mice following exercise. Additionally, exercise resulted in an increased expression of 
CD8 and decreased expression of Foxp3, markers for CTLs and Tregs, respectively.  
These alterations in immune cell parameters following exercise training were 
accompanied by a decrease in the percentage of large polyps. 
Animal models provide a tool to examine the effects of exercise on colon cancer 
in an experimental environment in which the type and intensity of exercise can be 
controlled.  They allow for detailed study of stage-specific responses to exercise, and 
help to identify the optimal mode, intensity and duration of exercise.  The benefits of 
exercise on colon cancer risk have been well documented in the Apc
Min/+
 mouse model of 
intestinal tumorigenesis (27, 67, 87, 90).  For example, nine weeks of treadmill running 
has been reported to decrease the total number of intestinal polyps by 29% as well as the 
number of large polyps (38%) in male mice in this model (91).  Similarly, exercise was 
reported to reduce total intestinal polyp number by 50% and the number of large polyps 
by 67% in this same model (67). Our findings are somewhat consistent with these 
investigations in that we report a 48% reduction in the number of large polyps. In contrast 
to the findings by Baltgalvis et al., we did not find a significant reduction in the number 
of total polyps; however, this is likely due to the smaller sample size in our study and/or 
to the slightly lower intensity of the exercise protocol (15m/min versus 18m/min).  
Nonetheless, the benefits of regular exercise training in the Apc
Min/+
 mouse model of 
intestinal tumorigenesis are evident across studies and it is clear from our findings and 
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those of others that exercise plays a larger role in reducing the progression of growth as 
opposed to the initiation of development, at least in this model. 
 In addition to polyp characteristics, we measured body weight, fat mass, spleen 
weight, and markers of anemia.  These outcomes have been associated with increased 
tumorigenesis and ultimately poorer prognosis in the Apc
Min/+
 mouse (7, 86).  Previous 
published data has shown that Apc
Min/+
 mice develop cachexia that is positively correlated 
with polyp burden (7).  In our study, the exercise mice tended to be heavier than the 
sedentary mice at 15 and 16 weeks of age, although this did not reach statistical 
significance.  Further, there were no differences in fat mass between the groups. 
However, the lack of positive findings is likely due to the timing of sacrifice as mice 
were sacrificed prior to the onset of severe cachexia.  This was done to eliminate any 
possible influence of cachexia or illness on the ability to perform the exercise protocol.  
Therefore, it is not surprising that we did not see a statistically significant effect of 
exercise at these time points.  Spleen weight has been associated with increased polyp 
number and systemic inflammation (92).  Our data indicate a reduction in spleen weight 
with exercise.  This is consistent with previously reported literature; Baltgalvis et al. also 
reported a reduction in spleen weight in male Apc
Min/+
 mice following exercise (92).  We 
have recently reported an increase in markers of anemia in this mouse model(86).  While 
exercise did prevent the characteristic decrease in Hct in these mice, the effect was not 
found to be statistically significant.  Again, this is likely due to the timing of sacrifice as 
in our previous study mice were sacrificed at 18 weeks, a time in which the disease is 
much more severe.  Thus, any benefits of exercise would likely be more evident had the 
mice been sacrificed at a later time point.   
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 We next examined the effects of exercise on markers associated with 
macrophages in the mucosal tissue.  Macrophages can represent up to 50% of the tumor 
mass producing a wide array of inflammatory mediators with pro-tumoral functions (14, 
15).  Further, abundance of tumor associated macrophages has been associated with poor 
prognosis in colon cancer (14-18, 24).  Our data show a reduction in the expression of 
F4/80, an overall macrophage marker, with exercise. This is consistent with a previous 
study by Baltgalvis et al. that reported a reduction in macrophage number following 
exercise training in this model (27).  Because it is now well accepted that macrophages 
constitute an extremely heterogeneous population that is divided into two main classes 
(M1 and M2) (14), we next examined the effects of exercise on expression of markers 
associated with both the M1 and M2 phenotype.  In general, it is thought that M1 
macrophages are cytotoxic against neoplastic cells, whereas M2 macrophages exert pro-
tumoral functions (14).  We report the novel finding that exercise reduces the expression 
of certain markers that are associated with the M1 (IL-12) and M2 (CD206, CCL17, 
CCL22 and Arg-1) phenotype in the mucosal tissue.  It is important to note that given the 
limited available tissue, macrophage markers were not measured in the polyps 
themselves.  However, previous data from our group shows a similar response for these 
outcomes when comparing the mucosal tissue and polyp tissue in this model (86). While 
our data suggests that a reduction in both M1 and M2 macrophages with exercise is 
associated with a reduction in polyp growth in this model, a greater understanding of the 
roles of each macrophage subset within the tumor microenvironment is necessary.      
 Given the reduction in macrophage markers with exercise, we next examined the 
effects of exercise on macrophage chemoattractants.  MCP-1 is a major player in 
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macrophage chemotaxis in the Apc
Min/+
 mouse (86).  In fact, we recently reported a link 
between macrophages and MCP-1 in this mouse model (86). Although our data indicate 
an exercise-induced decrease in the expression of macrophage associated markers in the 
mucosal tissue, we did not find a significant decrease in MCP-1.  Therefore, we also 
examined Fetuin A and CXCL14, both of which have been implicated in macrophage 
recruitment.  Fetuin A is a recently characterized macrophage chemoattractant that is also 
known to play a role in macrophage polarization (93).  While our results show a decrease 
in the expression of Fetuin A that is consistent with our macrophage findings, this did not 
reach statistical significance.  Similarly, there was no effect of exercise on CXCL14, a 
chemoattractant for activated tissue macrophages.  It is important to point out that only a 
subset of macrophage chemoattractants were measured in this study, thus it is possible 
that exercise may have impacted other chemokines. 
 One of the most important effector mechanisms of anti-tumor immunity is the 
activities of CTLs (33, 34).  For example, growth of B16 melanoma cells can be 
controlled in mice following the transfer of CD8+ cells (35).  On the other hand, Tregs 
have been linked to accelerated tumor growth and immune evasion due to their inhibitory 
actions on CTLs and helper T cells (36, 37).  The findings of the current study show an 
increased expression of CD8, and conversely, a decreased expression of Foxp3 in the 
mucosal tissue following exercise training.  While this is the first report of a favorable 
effect of exercise on CTLs and Tregs in a model of colon cancer, the evidence supporting 
exercise-induced alterations in immune function is far reaching.  In general, regular 
moderate exercise is thought to enhance immune function; however, these effects are 
likely dependent on a multitude of factors including individual characteristics, the type, 
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intensity and duration of exercise, and the stage of cancer. Although these findings 
support a positive effect of exercise on the T cell profile in a cancer model, it is important 
to point out that whether this is due to a direct effect of the exercise on these cell 
populations or an indirect effect that results from the reduction in large polyp number 
resulting from an entirely different mechanism could not be determined from this study.   
 Consistent with previous reports, we show a benefit of exercise training on 
reducing large polyp number in the Apc
Min/+
 mouse model of intestinal tumorigenesis.  
This was associated with alterations in the expression of immune markers in the mucosal 
tissue including a reduction in markers associated with M1 and M2 macrophages, an 
increase CD8 and a decrease in Foxp3.  Overall this data provides important new 
information on immune regulation as a possible mechanism for the benefits of exercise 




Figure 3.1.  Effects of exercise on body weight, visceral fat mass and spleen weight in 
Apc
Min/+
 mice.  Differences in body weight (A), visceral fat mass (B) and spleen weight 
(C) were examined in sedentary (Sed) and exercised (Ex) Apc
Min/+
 mice (n= 6-9/group) at 










































































Figure 3.2.  Effects of exercise on WBCs, RBCs, Hb and Hct in Apc
Min/+
 mice.  
Differences in WBC count (A), RBC count (B), Hb (C) and Hct (D) were examined in 
sedentary (Sed) and exercised (Ex) Apc
Min/+
 mice (n=6-9/group) at 16 weeks of age.  






















































Figure 3.3.  Effects of exercise on polyp number and size in Apc
Min/+
 mice.  
Differences in total polyp number (A) and polyp size (B) were examined in sedentary 
(Sed) and exercised (Ex) Apc
Min/+
 mice (n=6-9/group) at 16 weeks of age.  Values are 













































Figure 3.4.  Effects of exercise on gene expression of M1 and M2 associated 
phenotypic macrophage markers in Apc
Min/+
 mice.  Differences in gene expression of 
F4/80 (A), M1 macrophage markers (IL-12 (B) and IL-23 (C)), and M2 macrophage 
markers (CD206 (D), IL-10 I, IL-4 (F), CCL17 (G) and CCL22 (H)) were examined in 
sedentary (Sed) and exercised (Ex) Apc
Min/+
 mice (n=6-9/group) at 16 weeks of age in 
mucosal scrapings.  Values are means ± SEM.  *Significant difference (P<0.05). **Trend 






















































Figure 3.5.  Effects of exercise on gene expression of CTL and Treg cell markers in 
Apc
Min/+
 mice.  Differences in gene expression of CD8 (A), a marker for CTLs and 
Foxp3 (B), a marker for Tregs were examined in sedentary (Sed) and exercised (Ex) 
Apc
Min/+
 mice (n=6-9/group) at 16 weeks of age in mucosal scrapings.  Values are means 















































 Epidemiological evidence links colon cancer to chronic intestinal inflammation 
(54).  Further support for a role of inflammation in colon cancer comes from studies 
using mouse models that have been shown to be responsive to treatment with anti-
inflammatory agents, including both anti-inflammatory dietary supplements as well as 
non-steroidal anti-inflammatory drugs (NSAIDs) (39).  Despite this, the timing and 
magnitude of the inflammatory cytokine response in relation to tumorigenesis has not 
been characterized.  The first study used an established mouse model of intestinal 
tumorigenesis to examine this response in the Apc
Min/+
 mouse.  We show here for the first 
time the timing and magnitude of the inflammatory cytokine response in intestinal tissue 
across time in the Apc
Min/+ 
mouse.  These findings may have important implications for 
colon cancer.  Firstly, these results may contribute to the future development of 
biomarkers to assess colon cancer progression.  Our data shows a strong relationship 
between polyp progression and MCP-1 in a mouse model of colon cancer.  Future studies 
are necessary to fully evaluate the potential of these inflammatory cytokines as 
prognostic indicators for colon cancer.  Secondly, these data provide important new 
information that can be used for the determination of appropriate timing of effective 
treatments that can be used in the design of future investigations that target inflammatory 
processes in mouse models of colon cancer.  These data contribute to the growing 
evidence on the association between inflammation and colon cancer and provide 
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important new data that could be used in the development of biomarkers as well as in the 
design of future investigations of anti-inflammatory treatments. 
Macrophages play a key role in tumorigenesis; they are a major player in the 
inflammatory response that contributes to cellular transformation, promotion, apoptosis, 
proliferation, invasion, angiogenesis, and metastasis (1, 4, 14, 15, 73, 74).  MCP-1 has 
been identified as the most important chemokine for recruitment of macrophages to the 
tumor microenvironment (22).  However, the link between MCP-1, macrophages, 
inflammation, and tumorigenesis in colon cancer has not yet been established.  Through 




 mouse bred in our laboratory, we report the novel finding 
that MCP-1 is a link between macrophages, inflammation, and tumorigenesis in colon 
cancer.  In summary, we report that MCP-1 is an important regulator of macrophages, T 
cells, and inflammatory responses in the tumor microenvironment that can lead to 
increased polyp burden in the Apc
Min/+





 mouse that we developed in our laboratory, we show a decrease in 
overall polyp number and large polyp abundance that was consistent with a reduction in 
macrophage number, an alteration in T cell markers that are associated with improved 
immune surveillance, and a decrease in inflammatory processes in the polyp tissue and 
surrounding intestinal tissue as compared to MCP-1 sufficient Apc
Min/+
 mice. Given the 
important regulatory role of MCP-1 in these facets of cancer, development of effective 
pharmacological or antibody approaches to inhibit MCP-1 may have important 
implications for the prevention and/or treatment of colon cancer. 
There is an inverse relationship between physical activity and colon cancer risk 
(89).  A multitude of mechanisms, including immune function dysregulation, have been 
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implicated in this response.  Macrophages and T cells play a significant role in the 
pathogenesis of colon cancer and exercise can influence the actions of these cells; 
however, there is very little evidence on the benefits of exercise on macrophage and T 
cell responses in the settings of colon cancer.  We examined the effects of exercise on 
markers associated with macrophages and select T cell subsets in a mouse model of 
intestinal tumorigenesis in relation to polyp characteristics.  We show a benefit of 
exercise training on reducing large polyp number in the Apc
Min/+
 mouse.  This was 
associated with alterations in the expression of immune markers in the mucosal tissue 
including a reduction in markers associated with M1 and M2 macrophages, an increase 
CD8 and a decrease in Foxp3.  Overall this data provides important new information on 
immune regulation as a possible mechanism for the benefits of exercise training on 
reducing colon cancer progression. 
Overall, these data provide new information on the progression of inflammation 
in the Apc
Min/+
 mouse model of intestinal tumorigenesis as well as the importance of 
macrophages and cytokines in this process.  We have also shown a possible mechanism 
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